Foundations of Testosterone Disorder Management
Testosterone disorders represent a common yet often underdiagnosed set of conditions encountered in primary care and family practice. These disorders include hypogonadism (low testosterone) and, less commonly, testosterone excess (e.g., from exogenous use or tumors). For the FNP exam, you must differentiate primary from secondary hypogonadism, recognize clinical presentations, order and interpret appropriate laboratory tests, and manage replacement therapy safely while monitoring for adverse effects.[1] Mastery of this topic is essential because testosterone deficiency affects approximately 40% of men over age 45, and improper management can lead to cardiovascular, metabolic, and prostate-related complications.[2]
Clinical Terminology and Diagnostic Classification
- Hypogonadism: A clinical syndrome resulting from failure of the testes to produce physiological levels of testosterone and/or normal numbers of spermatozoa due to a disruption at one or more levels of the hypothalamic-pituitary-gonadal (HPG) axis.[1]
- Primary hypogonadism: Testicular failure causing low testosterone with elevated LH and FSH (hypergonadotropic). Causes include Klinefelter syndrome, cryptorchidism, chemotherapy, trauma, or infection (e.g., mumps orchitis).[1]
- Secondary hypogonadism: Hypothalamic/pituitary dysfunction resulting in low testosterone with low or inappropriately normal LH/FSH (hypogonadotropic). Causes include pituitary tumors, prolactinomas, hemochromatosis, obesity, chronic illness, opioid use, and anabolic steroid use.[3]
- Late-onset hypogonadism (LOH): Age-related decline in testosterone in older men, often associated with obesity, diabetes, and metabolic syndrome.[2]
- Testosterone replacement therapy (TRT): Exogenous administration of testosterone to restore physiological levels, available in various formulations (gels, injections, pellets, buccal tablets).[4]
- Eugonadal: Normal serum testosterone and normal spermatogenesis.
- Bioavailable testosterone: Free testosterone plus albumin-bound testosterone; more clinically relevant than total testosterone in certain conditions (e.g., obesity).[1]
Hypothalamic-Pituitary-Gonadal Axis Dysfunction
The HPG axis controls testosterone production. GnRH from the hypothalamus stimulates pituitary release of LH and FSH. LH acts on Leydig cells to produce testosterone; FSH acts on Sertoli cells to support spermatogenesis. Testosterone exerts negative feedback at the hypothalamus and pituitary.[1]
- Screening indications: Symptoms of low testosterone (low libido, erectile dysfunction, fatigue, depression, loss of muscle mass, anemia) AND a measured low morning total testosterone on two separate occasions.[3]
- Diagnostic workup: Measure total testosterone (preferably 8–10 AM). If low, repeat with LH, FSH, prolactin, and possibly free testosterone (especially if SHBG is abnormal).[1]
- Differentiate primary vs. secondary: Elevated LH/FSH = primary; low/inappropriate normal LH/FSH = secondary (prompt pituitary MRI).[3]
- Exclude contraindications before starting TRT: Prostate cancer (untreated), breast cancer, severe lower urinary tract symptoms (IPSS >19), untreated sleep apnea, hematocrit >50%, or desire for fertility.[4]
- Monitor during therapy: Check testosterone levels, hematocrit, PSA, and symptoms every 3–6 months initially, then annually.[4]
Systemic Manifestations of Testosterone Deficiency
| System | Findings |
|---|---|
| Sexual | Reduced libido, erectile dysfunction, decreased spontaneous erections, poor morning erections |
| Somatic | Decreased muscle mass and strength, increased body fat, decreased bone density, gynecomastia, loss of body hair, hot flashes |
| Psychological | Fatigue, depressed mood, irritability, decreased energy, poor concentration, sleep disturbances |
| Metabolic | Insulin resistance, metabolic syndrome, type 2 diabetes, dyslipidemia, anemia |
Laboratory and Imaging Workup Strategy
Laboratory Testing
- Total testosterone (morning draw, two separate days): Normal ~300–1000 ng/dL. <300 ng/dL with symptoms suggests deficiency.[1]
- Free testosterone (if SHBG levels are abnormal, e.g., in obesity, aging): Calculated or by equilibrium dialysis.[1]
- LH and FSH: Key to differentiate primary vs. secondary hypogonadism.
- Prolactin: Elevated in pituitary tumors (prolactinoma causing secondary hypogonadism).[3]
- Serum ferritin and iron studies: If hemochromatosis suspected.
- Karyotype: If primary hypogonadism with small testes suggests Klinefelter syndrome (47,XXY).
Imaging Studies
- Pituitary MRI: Indicated if secondary hypogonadism (low LH/FSH) and elevated prolactin or other pituitary deficits.[3]
- Dual-energy X-ray absorptiometry (DXA): For bone mineral density if osteoporosis risk (hypogonadism).
Pharmacologic and Non-Pharmacologic Interventions
Testosterone Replacement Therapy (TRT) Options
| Formulation | Dosing Examples | Advantages | Disadvantages |
|---|---|---|---|
| Transdermal gel (e.g., AndroGel 1.62%) | 1–2 pumps daily | Easy, flexible dosing | Risk of transfer to others; skin irritation |
| Intramuscular injection (testosterone cypionate or enanthate) | 100–200 mg every 1–2 weeks | Inexpensive, effective | Peak/valley fluctuations; injection pain |
| Long-acting injection (testosterone undecanoate) | 750 mg IM, then 4 weeks later, then every 10 weeks | Less frequent dosing | Requires office injection; rare pulmonary oil microembolism |
| Subcutaneous pellets | 600–1200 mg every 3–6 months | Steady levels, long duration | Minor incision; rare extrusion, infection |
| Buccal tablets (Striant) | 30 mg twice daily | No injection | Gum irritation, taste changes |
Non-Pharmacologic Management
- Lifestyle modification: Weight loss, exercise (especially resistance training), adequate sleep, and management of comorbidities (diabetes, obesity) can improve testosterone levels modestly.[2]
- Treat underlying causes: Discontinue opioids, manage prolactinomas (dopamine agonists), treat hemochromatosis (phlebotomy).[3]
- Fertility considerations: If desiring fertility, avoid exogenous testosterone (it suppresses endogenous production and spermatogenesis). Use hCG or GnRH pump if secondary hypogonadism.[1]
Adverse Effects and Contraindication Monitoring
- Cardiovascular risk: TRT may increase risk of major adverse cardiovascular events (MACE) in older men or those with known heart disease; use caution.[4]
- Polycythemia (elevated hematocrit): Most common adverse effect; monitor CBC; if Hct >54–55%, hold TRT, consider phlebotomy, or reduce dose.[4]
- Prostate concerns: TRT can stimulate growth of existing prostate cancer; screen with PSA and DRE before starting. Exacerbation of lower urinary tract symptoms (LUTS) may occur.[4]
- Gynecomastia: Due to peripheral aromatization of testosterone to estradiol; may be managed with dose reduction or aromatase inhibitors.
- Sleep apnea: TRT can worsen obstructive sleep apnea; assess risk and treat before initiating therapy.[4]
- Transdermal gel transfer: Warn patients to wash hands after application and cover site to prevent transfer to women or children (virilization).[4]
- Contraindications to TRT: Active prostate or breast cancer, severe LUTS, untreated severe sleep apnea, hematocrit >50%, desire for fertility (relative).[1]
Clinical Reasoning and Test-Taking Strategies
- Memory aid for workup: Before starting TRT, always check prostate (PSA/DRE), blood (CBC with Hct), and sleep (screen for apnea).
- Differentiation is key: High LH/FSH = primary (testicular failure). Low or inappropriately normal LH/FSH = secondary (pituitary/hypothalamic).
- Do not test total testosterone in the afternoon: Levels peak in the morning; a low afternoon level may be normal.
- TRT will not improve fertility: It suppresses spermatogenesis. For fertility in hypogonadism, consider hCG or letrozole instead.
- Common exam scenario: Obese man with low total testosterone but normal free testosterone; this is functional hypogonadism due to low SHBG—no TRT needed; treat obesity.
- Monitor for polycythemia: Most frequent lab abnormality; check Hct at 3–6 months.
- Absolute contraindication: Untreated prostate cancer; relative: untreated severe sleep apnea, Hct >50%, severe LUTS (IPSS >19).
- Known pseudohypogonadism: Sick day or acute inflammation can transiently suppress testosterone; do not diagnose during acute illness.
References & Sources
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., ... & Yialamas, M. A. (2018). Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. https://doi.org/10.1210/jc.2018-00229
- Mulligan, T., Frick, M. F., Zuraw, Q. C., Stemhagen, A., & McWhirter, C. (2006). Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International Journal of Clinical Practice, 60(7), 762–769. https://doi.org/10.1111/j.1742-1241.2006.00992.x
- The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE). (2019). Endocrine and metabolic disorders in the aging male: clinical practice guidelines. Endocrine Practice, 25(5), 487–510. https://doi.org/10.4158/EP-2018-0547
- U.S. Food and Drug Administration (FDA). (2015). FDA drug safety communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke. https://pubmed.ncbi.nlm.nih.gov/26292880/